{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:50Z","timestamp":1790286950134,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jaad.2017.03.038","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T10:15:29Z","timestamp":1501668929000},"page":"713-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib"],"prefix":"10.1016","volume":"77","author":[{"given":"Tina","family":"Bhutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Abrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia S.","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Sadetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivor","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Margaret","family":"Chren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Arron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaad.2017.03.038_bib1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US\u00a0population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"23","key":"10.1016\/j.jaad.2017.03.038_bib2","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.03.038_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13671-014-0069-y","article-title":"Advanced basal cell carcinoma: epidemiology and therapeutic innovations","volume":"3","author":"Mohan","year":"2014","journal-title":"Curr Dermatol Rep"},{"issue":"3","key":"10.1016\/j.jaad.2017.03.038_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archdermatol.2010.19","article-title":"Incidence estimate of nonmelanoma skin cancer in the United States, 2006","volume":"146","author":"Rogers","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2017.03.038_bib5","series-title":"FDA approves new treatment for most common type of skin cancer","author":"US Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.jaad.2017.03.038_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/907543","article-title":"Patched knockout mouse models of basal cell carcinoma","volume":"907543","author":"Nitzki","year":"2012","journal-title":"J Skin Cancer"},{"issue":"7","key":"10.1016\/j.jaad.2017.03.038_bib7","first-page":"457","article-title":"Malignant epithelial tumors, I: pathophysiology and clinical features","volume":"10","author":"Leverkus","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10","key":"10.1016\/j.jaad.2017.03.038_bib8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrc2503","article-title":"Basal cell carcinomas: attack of the hedgehog","volume":"8","author":"Epstein","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2017.03.038_bib9","first-page":"1","article-title":"Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease","volume":"650258","author":"G\u00f6ppner","year":"2011","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.jaad.2017.03.038_bib10","series-title":"Erivedge [prescribing information]","author":"Genentech","year":"2012"},{"issue":"6","key":"10.1016\/j.jaad.2017.03.038_bib11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.03.038_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjd.12840","article-title":"Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma","volume":"171","author":"Orouji","year":"2014","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.03.038_bib13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamadermatol.2014.583","article-title":"Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas","volume":"150","author":"Zhu","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.03.038_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000368350","article-title":"Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib","volume":"230","author":"Poulalhon","year":"2015","journal-title":"Dermatology (Basel)"},{"issue":"1","key":"10.1016\/j.jaad.2017.03.038_bib15","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2013.01.023","article-title":"Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib","volume":"69","author":"Iarrobino","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.03.038_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"23","key":"10.1016\/j.jaad.2017.03.038_bib17","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1158\/1078-0432.CCR-12-1796","article-title":"A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission","volume":"18","author":"Kaye","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jaad.2017.03.038_bib18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-3083.2012.04483.x","article-title":"Host risk factors for the development of multiple non-melanoma skin cancers","volume":"27","author":"Qureshi","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"17","key":"10.1016\/j.jaad.2017.03.038_bib19","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1158\/0008-5472.CAN-14-2999-T","article-title":"RAS\/MAPK activation drives resistance to SMO inhibition, metastasis, and tumor evolution in Shh pathway\u2013dependent tumors","volume":"75","author":"Zhao","year":"2015","journal-title":"Cancer Res"},{"issue":"7129","key":"10.1016\/j.jaad.2017.03.038_bib20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nature05489","article-title":"Promotion of HRAS-induced squamous carcinomas by a polymorphic variant of the patched gene in FVB mice","volume":"445","author":"Wakabayashi","year":"2007","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jaad.2017.03.038_bib21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jid.2012.403","article-title":"Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"133","author":"Chren","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.03.038_bib22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","article-title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","volume":"16","author":"Basset-Seguin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2017.03.038_bib23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaad.2017.03.038_bib24","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1055-9965.EPI-10-0243","article-title":"Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review","volume":"19","author":"Wheless","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.jaad.2017.03.038_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/jid.2013.304","article-title":"Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence","volume":"134","author":"Eisemann","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.03.038_bib26","series-title":"Vismodegib FDA approval","author":"US Food and Drug Administration","year":"2012"},{"issue":"5","key":"10.1016\/j.jaad.2017.03.038_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamadermatol.2015.5239","article-title":"Hedgehog blockade for basal cell carcinoma: coming at a (secondary neoplastic) price","volume":"152","author":"R\u00fcbben","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2017.03.038_bib28","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamadermatol.2016.2427","article-title":"Study on the risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma: not a case-control study (letter)","volume":"152","author":"Gjersvik","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2017.03.038_bib29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamadermatol.2016.2428","article-title":"Study on the risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma: not a case-control study (letter)","volume":"152","author":"Puig","year":"2016","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217304279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217304279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:43:12Z","timestamp":1759272192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217304279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0190962217304279"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.03.038","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}